Clinical Trials Logo
  1. Home
  2. Primary Breast Cancer
  3. NCT01019616

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Primary Breast Cancer Clinical Trial

Official title:
A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Clinical Trial Summary

The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(DDFS) in operable patients non-response to primary chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01019616
Study type Interventional
Source Peking University
Contact
Status Active, not recruiting
Phase Phase 3
Start date March 4, 2011
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05923177 - Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 Phase 1
Completed NCT01033162 - Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care N/A
Recruiting NCT03270007 - Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy Phase 4
Completed NCT00527449 - Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel Phase 2
Completed NCT04468113 - Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
Recruiting NCT03711877 - Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) Phase 3
Completed NCT04127019 - Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) Phase 3
Completed NCT01314833 - Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy Phase 3
Terminated NCT00172068 - Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow Phase 2
Completed NCT01049425 - Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer Phase 3
Recruiting NCT01840293 - Breast Cancer Proteomics and Molecular Heterogeneity
Completed NCT01779479 - Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) Phase 2
Completed NCT04277338 - Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 Phase 1
Recruiting NCT05445050 - mULM to Support Breast Cancer Diagnosis and Therapy N/A
Completed NCT00793377 - Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer Phase 3